|Values are valid only on day of printing.|
Evaluating patients with chronic myelogenous leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI) therapy, who are apparently failing treatment
This is the preferred initial test to identify the presence of acquired BCR-ABL1 mutations associated with TKI-resistance.
If BCR/ABL1 fusion type (p210, p190, p205 or p230) is not provided, BADX / BCR/ABL1, Qualitative, Diagnostic Assay will be performed at an additional charge.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Analysis of PCR Products by Sanger Sequencing
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)